Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 2714
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 May 2021 | Expected publication |
| 14 February 2020 | Note added to the project documents |
| 10 January 2020 | In progress. Referred October 28 2019 |
| 14 February 0202 | Suspended. Topic is now suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual